Core B: Testing and Biorepository

核心B摘要 核心B(测试和生物库)提供的服务对所有项目和核心都是必不可少的 血清学检测以改善新冠肺炎(STOP-COVID)中心的结果。血清学和病毒数据来自 三个项目将利用纵向收集的核心B来了解决定因素 急救者及其家庭接触者的流行率、传播和保护 仍处于接触SARS-CoV-2高风险的个人。核心B的主要目标将是：(I) 存档五年纵向研究期间收集的血清和细胞样本(目标1)，(2)执行病毒 对鼻咽拭子进行检测(目标2)，(3)产生关于水平、同种类型、特异性、 和所有项目的抗体中和活性(目标3)，以及(Iv)用所有Stop-CoVID解释数据 组件，继续关注产生新的、可测试的关于COVID传播和 保护战略。Core B的主要特点是：(I)我们拥有FDA批准的内部病毒检测， (Ii)一系列有效的抗体化验，以衡量不同的抗原特异性和免疫球蛋白同型；(Iii)化验 用于通过血清抗体中和病毒，以及(Iv)现有的COVID生物信息库基础设施。核心B 工作人员已经开发或验证了每一种分析方法。重要的是，核心B还确保了 来自俄亥俄州立大学的资金，以支持我们提议的大部分测试。内核A、B和C将连接到 数据/元数据的存储、安全和深入分析。项目1、3和核心A-C将协同 将我们团队生成的测试数据与SeroNet进行沟通，了解它们的直接影响和影响 我们对COVID病原学、发病机制和免疫的不断发展的认识。核心B将与 关于将这些数据传达给Stop-CoVID参与者的方法的项目3，重点是它们的解释， 目前的影响，以及它们将如何指导未来的缓解做法。总而言之，核心B将促进 收集、分析和解释第一级血清学和病毒qRT-PCR数据，这将产生新的 关于COVID传播和保护的假设(项目1-2，核心A和C)。因此，一体化的 核心B提供的服务和分析将从概念上推进所有项目，将有助于确定优先顺序 所有项目和核心的下游研究，并最终应确定阻止COVID的新方法 或抑制其传播。

CORE B SUMMARY The services provided by Core B (Testing and Biorepository) will be essential for all Projects and Cores in the Serological Testing to Improve Outcomes from COVID-19 (STOP-COVID) Center. Serology and viral data from Core B, collected longitudinally, will be leveraged by the three Projects to understand determinants of prevalence, transmission, and protection in first responders and their household contacts, a cohort of individuals who remain at high risk for exposure to SARS-CoV-2. The major goals for Core B will be to: (i) archive serum and cell samples collected during the five-year longitudinal study (Aim 1), (ii) perform virus testing on nasopharyngeal swabs (Aim 2), (iii) generate first-tier serology data on levels, isotypes, specificities, and neutralization activities of antibodies for all Projects (Aim 3), and (iv) interpret data with all STOP-COVID components, keeping a focus on producing new, testable hypotheses about COVID transmission and strategies for protection. Key attributes of Core B are that we have (i) in-house, FDA-approved testing for virus, (ii) a battery of validated antibody assays that measure distinct antigen specificities and Ig isotypes, (iii) assays for virus neutralization by serum antibodies, and (iv) an existing COVID biorepository infrastructure. Core B personnel have either developed or validated each of these assays. Importantly, Core B has also secured funding from OSU to support the bulk of our proposed testing. Cores A, B, and C will interface for storage, security, and deep analysis of data/metadata. Projects 1, 3, and Cores A-C will synergize to communicate testing data generated by our group to SeroNet, with regard to their immediate impact and on our evolving knowledge about COVID etiology, pathogenesis, and immunity. Core B will work closely with Project 3 on methods to communicate these data to STOP-COVID participants, focusing on their interpretation, current impact, and how they will guide future practices for mitigation. In summary, Core B will facilitate the collection, analysis, and interpretation of first-tier serological and viral qRT-PCR data, which will generate new hypotheses about COVID transmission and protection (Projects 1-2, Cores A and C). Thus, the integrative services and analyses provided by Core B will advance all Projects conceptually, will facilitate prioritization of downstream studies by all Projects and Cores and, ultimately, should identify new approaches to stop COVID or inhibit its transmission.